Lineage Cell Therapeutics

Lineage, formerly known as BioTime Inc., is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. The company changed its name to Lineage Cell Therapeutics less than one year following their appointment of a new CEO, Brian Culley, and completing a series of corporate transactions including the distribution of AgeX Therapeutics, the acquisition of Asterias Biotherapeutics and conducting management changes which altogether focused the company mission on developing novel therapies based on directed differentiation and transplant of specific cell types.[6][7][8] Since then, Lineage’s focus has been to develop therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. Specifically, Lineage is testing therapies to treat dry age-related macular degeneration, spinal cord injuries, and non-small cell lung cancer. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. From this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are transplanted into a patient either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.[1]

Lineage has three allogeneic, or “off-the-shelf,” cell therapy programs in clinical development:

●OpRegen®, a single-injection retinal pigment epithelium cell replacement therapy currently in a Phase 1/2a multicenter clinical trial for the treatment of advanced dry age-related macular degeneration (“AMD”) with geographic atrophy (GA).[9][3] There currently are no therapies approved by the U.S. Food and Drug Administration (“FDA”) for dry AMD, which accounts for approximately 85-90% of all AMD cases and is the leading cause of blindness in people over the age of 60.[10] Interim data from 9 months of follow-up post-injection for Cohort 4 was reported in September 2021, highlights improved baseline visions and smaller areas of GA compared to prior cohorts. Overall, OpRegen has proven to be well tolerated to date with no serious adverse events not previously reported. Overall, 8/12 of Cohort 4 patients' treated eyes showed above baseline visual acuity at the last assessment, while 9/12 of the patients' untreated eyes were below baseline visual acuity at the same assessment interval.[9]

●OPC1, an oligodendrocyte progenitor cell therapy currently in a Phase 1/2a multicenter clinical trial for acute spinal cord injuries (“SCI”).[11][4] This clinical trial has been partially funded by the California Institute for Regenerative Medicine (CIRM).[12]

●VAC2, a cancer immunotherapy of antigen-presenting dendritic cells currently in a Phase 1 clinical trial in non-small cell lung cancer.[13][5] This clinical trial is being funded and conducted by Cancer Research UK, the world’s largest independent cancer research charity.[14]

Lineage's subsidiaries include:

(1) Includes shares owned by Lineage and ESI

Lineage’s Board of Directors includes:

• Alfred D. Kingsley, B.S., J.D. – Chairman of the Board[19] [20]
• Deborah Andrews, B.S. - Director[19][20]
• Dipti Amin, MBBS, FFPM, MRCGP, DCPSA, DCH, DRCOG, DGM - Director[19][20]
• Don M. Bailey, B.S., M.B.A. - Director[19][20]
• Neal C. Bradsher, C.F.A. - Director[19][20]
• Brian M. Culley, B.S., M.S., M.B.A. - Director[19][20]
• Anula Jayasuriya, M.D., Ph.D., M.B.A. - Director[19][20]
• Michael H. Mulroy, B.A., J.D. - Director[19][20]
• Angus C. Russel, D.B.A. – Director[19][20]

• Official website

• Business data for Lineage Cell Therapeutics:
  • Google Finance
  • Yahoo! Finance
  • Bloomberg
  • Reuters
  • SEC filings